Oral GLP-1s Widen AIOS Addressable Market

This matters because AIOS is built around moving patients through a lightweight prescribing workflow, not around any one drug format. A patient taking a tablet still fills out the same eligibility form, gets the same async clinician review, receives the same refill cadence, and can be served by the same pharmacy and support stack. The only real change is the package that ships, which makes oral GLP-1s a fast way to convert people who balk at needles into the same recurring care model.

• AIOS already runs a standardized GLP-1 wrapper, paid ads into intake form, clinician review, dose titration, side effect monitoring, and monthly fulfillment. That ops layer was designed to scale volume without adding much headcount, so an oral version can slot into the same funnel with minimal rework.
  2 sacra
• The UK approval happened on 11 June 2026, when the MHRA cleared the first GLP-1 tablet for weight loss, oral semaglutide under the Wegovy brand. That gave UK telehealth and pharmacy operators a new front door product for weight loss patients who prefer pills to injections.
  1 gov
• This follows the same playbook used by Ro and Hims, where the core asset is not the medication itself but the consumer acquisition and prescription machine around it. AIOS is narrower, focused on GLP-1s across brands and geographies, so each new formulation deepens one existing workflow instead of creating a new service line.
  2 sacra 3 sacra

Going forward, oral GLP-1s should make AIOS look less like an injectable only weight loss clinic and more like a broader metabolic care storefront. As more patients enter through the easier pill option, AIOS can extend them into longer term obesity, prediabetes, and cardiometabolic management on the same recurring infrastructure.